The One-Month DAPT with Ticagrelor In CABG PatieNts Trial (ODIN)

ODIN is an investigator-initiated prospective, international, multi-center, randomized open-label trial of 700 subjects undergoing CABG for SIHD. Eligible patients will be enrolled before CABG and randomized after CABG in a 1:1 manner to ticagrelor in addition to ASA or ASA alone for 1 month (Figure 2). The study drug (ticagrelor) will be administered after randomization (when there is no or minimal risk of surgical bleeding based on the surgeon’s evaluation) and no later than 48 hours after CABG. Background low-dose ASA will be administered within 6 hours and no later than 24 hours after CABG according to current guideline recommendations and dosing recommendations for ticagrelor.